ReviewFrontiers in pharmacology2021
Therapeutic Potential of Annexins in Sepsis and COVID-19.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Dual engagement of Spike and ACE2 by annexin A5 contributes to pleiotropic SARS-CoV-2 inhibition.Scientific reports · 2026Article
- Immunoproteomic insights into inflammatory diseases of the critically endangered black rhinoceros (Diceros bicornis).Scientific reports · 2026Article
- Chios Mastic Gum Extract Enhances Antioxidant Defense in Zebrafish.International journal of molecular sciences · 2025Article
- Changes in Placentas of Pregnant Women Infected with COVID-19.International journal of molecular sciences · 2025Article
- Annexin A5 ameliorates HMolecular biology reports · 2025Article
- Annexin A3 Represses Endothelial Permeability and Inflammation During Sepsis via Actin Cytoskeleton Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Newly Established Anoikis-Associated Genes Predict the Prognosis of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Revealing potential signaling pathways and hub genes related to monocytes in sepsis survivors and non-survivors based on single-cell RNA-seq and bulk RNA-seq data.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- ANXA5: related mechanisms of osteogenesis and additional biological functions.Frontiers in cell and developmental biology · 2025Review
- New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Annexin A5 in Patients With Severe COVID-19 Disease: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Feasibility Trial.Critical care explorations · 2023Article
- Recent Advances of Proteomics in Management of Acute Kidney Injury.Diagnostics (Basel, Switzerland) · 2023Review
- Annexin A5 Inhibits Endothelial Inflammation Induced by Lipopolysaccharide-Activated Platelets and Microvesicles via Phosphatidylserine Binding.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Pharmacokinetics of recombinant human annexin A5 (SY-005) in patients with severe COVID-19.Frontiers in pharmacology · 2023Article
- Article
- Therapeutic potential for targeting Annexin A1 in fibrotic diseases.Genes & diseases · 2022Review
- New Insights on Effects of Glucocorticoids in Patients With SARS-CoV-2 Infection.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Review
- An Overview of Cell Membrane Perforation and Resealing Mechanisms for Localized Drug Delivery.Pharmaceutics · 2022Review
- Exploration of cerebral vasospasm from the perspective of microparticles.Frontiers in neuroscience · 2022Review
- Integrated Single Cell and Bulk RNA-Seq Analysis Revealed Immunomodulatory Effects of Ulinastatin in Sepsis: A Multicenter Cohort Study.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a continuing problem in modern healthcare, with a relatively high prevalence, and a significant mortality rate worldwide. Currently, no specific anti-sepsis treatment exists despite decades of research on developing potential therapies. Annexins are molecules that show efficacy in preclinical models of sepsis but have not been investigated as a potential therapy in patients with sepsis. Human annexins play important roles in cell membrane dynamics, as well as mediation of systemic effects. Most notably, annexins are highly involved in anti-inflammatory processes, adaptive immunity, modulation of coagulation and fibrinolysis, as well as protective shielding of cells from phagocytosis. These discoveries led to the development of analogous peptides which mimic their physiological function, and investigation into the potential of using the annexins and their analogous peptides as therapeutic agents in conditions where inflammation and coagulation play a large role in the pathophysiology. In numerous studies, treatment with recombinant human annexins and annexin analogue peptides have consistently found positive outcomes in animal models of sepsis, myocardial infarction, and ischemia reperfusion injury. Annexins A1 and A5 improve organ function and reduce mortality in animal sepsis models, inhibit inflammatory processes, reduce inflammatory mediator release, and protect against ischemic injury. The mechanisms of action and demonstrated efficacy of annexins in animal models support development of annexins and their analogues for the treatment of sepsis. The effects of annexin A5 on inflammation and platelet activation may be particularly beneficial in disease caused by SARS-CoV-2 infection. Safety and efficacy of recombinant human annexin A5 are currently being studied in clinical trials in sepsis and severe COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.